Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Thoracic 1 Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 49 Fluorouracil 46 Capecitabine 41 Cisplatin 36 Gemcitabine 29 Leucovorin 27 Bevacizumab 21 Drug Therapy 20 Paclitaxel 15 Folfox protocol 15 Radiotherapy 14 Irinotecan 14 apatinib 11 Neoadjuvant Therapy 11 Docetaxel 11 sintilimab 9 S 1 (combination) 9 Sorafenib 8 Nivolumab 8 Trastuzumab 7 Surgical Procedures, Operative 7 Magnetic Resonance Spectroscopy 7 lenvatinib 6 atezolizumab 6 XELOX 6 Cetuximab 6 Albumin-Bound Paclitaxel 6 130-nm albumin-bound paclitaxel 6 tislelizumab 5 pembrolizumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Tyrosine Kinase Inhibitors × Gastrointestinal × Clear all

NCT02794337 2022-04-27

TACE-SBRT

Tata Memorial Hospital

Phase 2/3 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡